Institute of Applied Health Sciences
University of Aberdeen
DATABASE REVIEW
Department of Medicine & Therapeutics
Grampian University Hospitals
NHS Trust
COLORECTAL INITIATIVE
TUMOUR DATABASE
Colorectal Initiative Tumour Database
Jan 2002
DATABASE CODE: CIT
Page 1
Institute of Applied Health Sciences
University of Aberdeen
Contents
Introduction
3
History
3
Overview of Database
3
Database Structure
4
Main Table Summary
5
Colorectal Initiative Tumour Data
5
Associated Publications
6
Colorectal Initiative Tumour Database
Jan 2002
DATABASE CODE: CIT
Page 2
Institute of Applied Health Sciences
University of Aberdeen
Introduction
History
The Colorectal Initiative Tumour data has been stored in Excel since July 1994 and populated with
clinical details collected for colorectal tumours and adjacent uninvolved tissues. Molecular analysis of
samples provides the basis for determining potential predictive and prognostic markers and novel
therapeutic targets.
Colorectal cancer is a commonly diagnosed cancer ranked third after lung and breast cancer.
Overview of Database
The Colorectal Initiative Tumour data is held in Excel on a Personal Computer within the Institute of
Medical Sciences. Data extracts from Excel are imported into Statistical Package for Social Scientists
(SPSS) files for statistical analysis.
Basic data held in Excel is detailed in the Main Table Definitions Section.
Colorectal Initiative Tumour Database
Jan 2002
DATABASE CODE: CIT
Page 3
Institute of Applied Health Sciences
University of Aberdeen
Database Structure
COLORECTAL
INITIATIVE
TUMOUR DATA
Colorectal Initiative Tumour Database
Jan 2002
DATABASE CODE: CIT
Page 4
Institute of Applied Health Sciences
University of Aberdeen
Main Table Summary
Colorectal Initiative Tumour Data

Patient Identification / Sex / Date of Birth

Date of Death

Date and Time of Surgery

Hospital / Surgeon

Biopsy Number / Tumour Site / Tumour Size

Location Normal Tissue with Respect to Tumour

Diagnosis / Duke’s Stage / Date of Diagnosis

Operation Type

Node and TMN Staging Data

Date of Cancer Recurrence

Date of Follow-up / Treatment

Metastases sites / Other Tumours

Chemotherapy Details

Transfusions prior to Treatment

Carcinoembryonic Antigen Levels at Diagnosis and Start of Treatment

Liver Function Tests
Colorectal Initiative Tumour Database
Jan 2002
DATABASE CODE: CIT
Page 5
Institute of Applied Health Sciences
University of Aberdeen
Associated Publications
Cassidy J.
Colorectal cancer.
Geriatric Medicine. 26: 31-33, 1996.
Cassidy J.
Iatrogenic chest pain - 5-Fluorouracil cardiotoxicity.
Quarterly Journal of Medicine. 89: 953-955, 1996.
Dirix LY, Tonnesen F, Cassidy J, Epelbaum R, ten Bokkel huinink WW, Pavlidis N, Gamucci T,
Wolff I, TeVelde A, Lan J, Verweij J.
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC
Early Clinical Studies Group.
European Journal of Cancer. 32: 2019-22, 1996.
Hughes MJ, Soukop M, Kerr DJ, McGregor K, Blackburn N, Cassidy J.
A pilot study of combination therapy with interferon alfa 2A and 5-fluorouracil in metastatic carcinoid
tumours and malignant endocrine pancreatic tumours.
Annals of Oncology. 7: 208-210, 1996.
Cotton S, Sharp L, Little J.
The adenoma-carcinoma sequence and prospects for the prevention of colorectal neoplasia.
Critical Review of Oncogenesis. 7: 293-342, 1996.
Benamouzig R, Chaussade S, Little J, Munoz N, Rautureau J, Couturier D.
Aspirin, NSAIDs and colorectal carcinogenesis.
Gastro Clinical Biology. 21: 188-196, 1997.
Schuller J, Cassidy J, Reigner B.
Tumor selective activation of capecitabine in colorectal cancer patients.
Onkologie. 20: 189, 1997.
Seymour MT, Stenning SP, Cassidy J, on behalf of the Colorectal working Party of the UK Medical
Research Council. Attitudes and practice in the management of metastatic colorectal cancer in Britain.
Clinical Oncology. 9: 248-251, 1997.
Wattanatorn W, McLeod HL, Macklon F, Reid M, Kendle KE, Cassidy J.
A comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma and red blood cells in
patients with colorectal cancer.
Pharmacotherapy. 17: 881-886, 1997.
McLeod HL, Sludden J, Murray GI, Keenan RA, Davidson AI, Park K, Koruth M, Cassidy J.
Characterisation of dihydropyrimidine dehydrogenase in human colorectal tumours.
British Journal of Cancer. 77: 461-465, 1998.
Ridge SA, Sludden J, Wei X, Brown O, Fernandez-Salguero P, Canney P, Gonzalez FJ, Cassidy J.
Dihydropyrimidine dehydrogenase pharmacogenetics in colorectal cancer patients.
British Journal of Cancer. 77: 497-500, 1998.
Colorectal Initiative Tumour Database
Jan 2002
DATABASE CODE: CIT
Page 6
Institute of Applied Health Sciences
University of Aberdeen
Ahmed F, Johnston SJ, Cassidy J, O’Kelly T, Binnie N, Murray GI, Van Gennip AH, Abeling NGGM,
Knight S, McLeod HL.
Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors.
Journal of Clinical Oncology.17: 2439-2445, 1999.
Campbell ND, Ritchie LD, Cassidy J, Little J.
Systematic review of cancer treatment programmes in remote and rural areas.
British Journal of Cancer. 80: 1275-1280, 1999.
Curran S, Murray GI.
Matrix metalloproteinases in tumour invasion and metastasis.
Journal of Pathology. 189: 300-308, 1999.
Johnston SJ, Ridge SA, Cassidy J, McLeod HL.
Regulation of dihydropyrimidine dehydrogenase in colorectal cancer.
Clinical Cancer Research. 5: 2566-2570, 1999.
Little J
Problems and approaches in investigating the role of micronutrients in the aetiology of cancer in
humans.
British Medical Bulletin. 55: 600-618, 1999.
Bissett D, Ahmed F, McLeod HL, Cassidy J.
Oral fluoropyrimidines in the treatment of colorectal cancer.
Clinical Oncology. 12: 240-245, 2000.
Boonsong A, Marsh S, Rooney PH, Stevenson DAJ, Cassidy J, McLeod HL.
Characterisation of the topoisomerase 1 locus in human colorectal cancer.
Cancer Genetics and Cytogenetics. 121: 56-60, 2000.
Brockton N, Little J, Sharp L, Cotton, SC.
N-Acetyltransferase polymorphisms and colorectal cancer:
A HuGE review American Journal of Epidemiology. 151: 846-861, 2000.
Campbell NC, Elliott AM, Sharp L, Ritchie LD, Cassidy J, Little J.
Rural factors and survival from cancer: analysis of Scottish cancer registrations.
British Journal of Cancer. 82: 1863-1866, 2000.
Cassidy J.
Improving therapy of colorectal cancer with new agents.
Medscape (web publisher). Http://oncology.medscape.com/Medscape/oncology/Treatment.
Release date August 15th 2000.
Cassidy J.
Review of Oxaliplatin: An active platinum agent in colorectal cancer.
International Journal of Clinical Practice. 54: 399-402, 2000.
Cassidy J.
Efficacy of capecitabine in colorectal cancer.
Case Studies in Oncology. 2: 1-6, 2000.
Colorectal Initiative Tumour Database
Jan 2002
DATABASE CODE: CIT
Page 7
Institute of Applied Health Sciences
University of Aberdeen
Cassidy J.
Thymidylate Synthase inhibitors in colorectal cancer.
Seminars in Oncology. 2: 83-88, 2000.
Cotton SC, Sharp L, Little J, Brockton N.
Glutathione S-transferase polymorphisms and colorectal cancer:
A HuGE review American Journal of Epidemiology. 151: 7-32, 2000.
Curran S, Murray GI.
Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis.
European Journal of Cancer. 36: 1621, 2000.
Curran S, McKay JA, McLeod HL, Murray GI.
Laser capture microscopy.
Journal of Clinical Pathology. 53: 64-68, 2000.
DeGramont A, Figer M, Seymour M, Homerin M, Hmissi A, Cassidy J, et al.
Leucovorin and Flourouracil with or without Oxaliplatin as first line treatment in advanced colorectal
cancer.
Journal of Clinical Oncology. 18: 2938-2947, 2000.
Jaffrey RG, Pritchard SC, Clark C, Murray GI, Cassidy J, Kerr KM, et al.
Genomic instability at the BUB 1 locus in colorectal cancer, but not in non-small cell lung cancer.
Cancer Research. 60: 4349-4352, 2000.
McKay JA, Douglas JJ, Ross VG, Curran S, Murray GI, Cassidy J, McLeod HL.
Cyclin D1 protein expression and gene polymorphism in colorectal cancer.
International Journal of Cancer. 88: 77-81, 2000.
McKay JA, Lloret C, Murray GI, Johnston PG, Bicknell R, Cassidy J, McLeod HL.
Application of the enrichment approach to identify putative markers of response to 5-fluorouracil
therapy in advanced colorectal cancer.
International Journal of Oncology. 17: 153-158, 2000.
McKay JA, Douglas JJ, Ross VG, Curran S, Ahmed FYA, Loane JF, Murray GI and McLeod HL.
Expression of cell cycle control proteins in primary colorectal tumors does not always predict
expression in lymph node metastases.
Clinical Cancer Research 6: 1113-1118, 2000.
Schuller J, Cassidy J, Dumont E, Roos B, Durston S, Banken C, Uton M, Mori K, Weidekamm E,
Reigner.
Preferential activation of capecitabine in tumour following oral administration in colorectal cancer
patients.
Cancer Chemotherapy and Pharmacology. 45: 291-297, 2000.
Van Cutsem E, Finlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L, et al.
Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal
cancer: results of a randomized phase II study.
Journal of Clinical Oncology. 18: 1337-1345, 2000.
Colorectal Initiative Tumour Database
Jan 2002
DATABASE CODE: CIT
Page 8
Institute of Applied Health Sciences
University of Aberdeen
Yoon H, Benamouzig R, Little J, et al.
Systematic review of epidemiological studies on meat, dairy products and egg consumption and risk of
colorectal adenomas.
European Journal of Cancer Prevention. 9: 151-164, 2000.
Benamouzig R, Yoon H, Little J, Benamouzig R, Yoon H, Little J, Martin A, Couturier D, Deyra J,
Coste, T, Chaussade, S.
APACC, a French prospective study on aspirin efficacy in reducing colorectal adenoma recurrence:
design and baseline findings.
European Journal of Cancer Prevention. 10: 327-335, 2001.
Campbell NC, Elliott AM, Sharp L, Ritchie LD, Cassidy J, Little J.
Rural and urban differences in stage at diagnosis of colorectal and lung cancers.
British Journal of Cancer. 84: 910-914, 2001.
Cassidy J.
Xeloda in colorectal cancer.
International Journal of Clinical Practice. 55: 1-3, 2001.
Collie-Duguid ESR, Johnston SJ, Boyce L, Smith N, Cowieson A, Cassidy J, Murray GI, McLeod HL.
Thymidine phosphorylase and dihydropyrimidine dehydrogenase protein expression in colorectal
cancer.
International Journal of Cancer. 94: 297-301, 2001
Dusseau C, Murray GI, Keenan RA, O'Kelly T, Krokan HE, McLeod HL.
Analysis of Uracil DNA glycosylase in human colorectal cancer.
International Journal of Oncology. 18: 393-399, 2001.
Lawrie LC, Fothergill JE, Murray GI.
Spot the differences: Proteomics in cancer research.
The Lancet Oncology. 2: 270-277, 2001.
Little J.
Multivitamins, folate, and colon cancer.
Gut. 48: 12-13, 2001.
Marsh S, McKay JA, Cassidy J, McLeod HL.
Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer.
International Journal of Oncology. 19: 383-386, 2001.
Rooney PH, Boonsong A, McKay J, Marsh S, Stevenson DAJ, Murray GI, Curran S, Haites NE,
Cassidy J, McLeod HL.
Colorectal cancer genomics: evidence for multiple genotypes which influence survival.
British Journal of Cancer. 85: 1492-1498, 2001.
Twelves C, Boyer M, Findlay M, Cassidy J et al.
Capecitabine improves medical resource use compared to 5-fluorouracil plus leucovorin in a phase III
trial conducted in patients with advanced colorectal cancer.
European Journal of Cancer. 37: 597-604, 2001.
Colorectal Initiative Tumour Database
Jan 2002
DATABASE CODE: CIT
Page 9
Institute of Applied Health Sciences
University of Aberdeen
Cassidy J
New drugs in colorectal cancer.
Medicine Matters. In press 2001.
Lawrie L, Curran S, McLeod HL, Fothergill JE, Murray GI.
Application of laser capture microdissection and proteomics in colon cancer.
Journal of Clinical Pathology: Molecular Pathology. In press 2001.
McKay JA, Githang’a J, Indalo A, Li T, Liu X, Ameyaw M-M, Ofori-Adjei D and McLeod HL.
Distinct differences in a cyclin D1 single nucleotide polymorphism between ethnic groups.
GeneScreen. In press 2001.
Bain NSC, Campbell NC, Ritchie LD, Cassidy J.
Striking the right balance in colorectal cancer care – a qualitative study of rural and urban patients.
Submitted.
Cassidy J, Twelves C, Van Cutsem E et al on behalf of the Capecitabine colorectal cancer study group.
First-line capecitabine therapy in metastatic colorectal cancer: A favourable safety profile compared to
IV 5-fluorouracil and leucovorin. Submitted.
Cassidy J, Diaz-Rubio E, Evans J, Taberno J, Bissett D, Regueiro P.
Capecitabine in combination with oxaliplatin: A phase I study in patients with advanced or metastatic
solid tumours. Submitted.
Marsh S, McKay JA, Cassidy J, McLeod HL.
Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Submitted.
Marsh S, McKay JA, Curran S, Cassidy J, McLeod HL.
Primary colorectal tumour is not an accurate predictor of thymidylate synthase in lymph node
metastasis. Submitted.
McKay JA, Loane JF, Ross VG, Ameyaw M-M, Murray GI, Cassidy J, McLeod HL.
C-erbB-2 is not a major factor in the development or progression of colorectal cancer. Submitted.
McKay JA, Douglas JJ, Ross VG, Curran S, Loane JF, Ahmed FY, Cassidy J, McLeod HL, Murray
GI.
Analysis of key cell cycle checkpoint proteins in colorectal tumours. Submitted.
McKay JA, Douglas JJ, Ross VG, Curran S, Loane JF, Ahmed FY, Cassidy J, McLeod HL, Murray
GI.
A comprehensive analysis of G1/S checkpoint proteins in colorectal tumours. Submitted.
McKay JA, Murray LJ, Curran S, Ross VG, Clark C, Murray GI, Cassidy J, McLeod HL.
Evaluation of the epidermal growth factor (EGFR) in colorectal tumours and lymph node metastases.
Submitted.
Van Cutsem E, Twelves C, Cassidy J et al on behalf of Xeloda study group.
Oral xeloda compared with intravenous 5-fluorouracil plus leucovorin (Mayo clinic regimen) in
patients with metastatic colorectal cancer: Results of a large phase III trial. Submitted.
Colorectal Initiative Tumour Database
Jan 2002
DATABASE CODE: CIT
Page 10